Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.
Identifieur interne : 000343 ( Main/Exploration ); précédent : 000342; suivant : 000344Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.
Auteurs : O. Wichmann [Allemagne] ; P. Stocker ; G. Poggensee ; D. Altmann ; D. Walter ; W. Hellenbrand ; G. Krause ; T. EckmannsSource :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [ 1560-7917 ] ; 2010.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Allemagne (épidémiologie), Entretiens comme sujet (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Résultat thérapeutique (MeSH), Sous-type H1N1 du virus de la grippe A (isolement et purification), Vaccins antigrippaux (MeSH), Épidémies de maladies (MeSH).
- MESH :
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- épidémiologie : Allemagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Entretiens comme sujet, Humains, Jeune adulte, Résultat thérapeutique, Vaccins antigrippaux, Épidémies de maladies.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Disease Outbreaks (MeSH), Germany (epidemiology), Humans (MeSH), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza Vaccines (MeSH), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Interviews as Topic (MeSH), Middle Aged (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical : Influenza Vaccines.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Disease Outbreaks, Humans, Interviews as Topic, Middle Aged, Treatment Outcome, Young Adult.
Abstract
During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).
PubMed: 20460094
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.</title><author><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name><affiliation wicri:level="3"><nlm:affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Stocker, P" sort="Stocker, P" uniqKey="Stocker P" first="P" last="Stocker">P. Stocker</name></author><author><name sortKey="Poggensee, G" sort="Poggensee, G" uniqKey="Poggensee G" first="G" last="Poggensee">G. Poggensee</name></author><author><name sortKey="Altmann, D" sort="Altmann, D" uniqKey="Altmann D" first="D" last="Altmann">D. Altmann</name></author><author><name sortKey="Walter, D" sort="Walter, D" uniqKey="Walter D" first="D" last="Walter">D. Walter</name></author><author><name sortKey="Hellenbrand, W" sort="Hellenbrand, W" uniqKey="Hellenbrand W" first="W" last="Hellenbrand">W. Hellenbrand</name></author><author><name sortKey="Krause, G" sort="Krause, G" uniqKey="Krause G" first="G" last="Krause">G. Krause</name></author><author><name sortKey="Eckmanns, T" sort="Eckmanns, T" uniqKey="Eckmanns T" first="T" last="Eckmanns">T. Eckmanns</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20460094</idno><idno type="pmid">20460094</idno><idno type="wicri:Area/Main/Corpus">000332</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000332</idno><idno type="wicri:Area/Main/Curation">000332</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000332</idno><idno type="wicri:Area/Main/Exploration">000332</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.</title><author><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name><affiliation wicri:level="3"><nlm:affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Stocker, P" sort="Stocker, P" uniqKey="Stocker P" first="P" last="Stocker">P. Stocker</name></author><author><name sortKey="Poggensee, G" sort="Poggensee, G" uniqKey="Poggensee G" first="G" last="Poggensee">G. Poggensee</name></author><author><name sortKey="Altmann, D" sort="Altmann, D" uniqKey="Altmann D" first="D" last="Altmann">D. Altmann</name></author><author><name sortKey="Walter, D" sort="Walter, D" uniqKey="Walter D" first="D" last="Walter">D. Walter</name></author><author><name sortKey="Hellenbrand, W" sort="Hellenbrand, W" uniqKey="Hellenbrand W" first="W" last="Hellenbrand">W. Hellenbrand</name></author><author><name sortKey="Krause, G" sort="Krause, G" uniqKey="Krause G" first="G" last="Krause">G. Krause</name></author><author><name sortKey="Eckmanns, T" sort="Eckmanns, T" uniqKey="Eckmanns T" first="T" last="Eckmanns">T. Eckmanns</name></author></analytic><series><title level="j">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</title><idno type="eISSN">1560-7917</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Disease Outbreaks (MeSH)</term><term>Germany (epidemiology)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza Vaccines (MeSH)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Interviews as Topic (MeSH)</term><term>Middle Aged (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (épidémiologie)</term><term>Entretiens comme sujet (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Vaccins antigrippaux (MeSH)</term><term>Épidémies de maladies (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Disease Outbreaks</term><term>Humans</term><term>Interviews as Topic</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Entretiens comme sujet</term><term>Humains</term><term>Jeune adulte</term><term>Résultat thérapeutique</term><term>Vaccins antigrippaux</term><term>Épidémies de maladies</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20460094</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>18</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill.</ISOAbbreviation></Journal><ArticleTitle>Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">19561</ELocationID><Abstract><AbstractText>During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocker</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Poggensee</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hellenbrand</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Eckmanns</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><noCountry><name sortKey="Altmann, D" sort="Altmann, D" uniqKey="Altmann D" first="D" last="Altmann">D. Altmann</name><name sortKey="Eckmanns, T" sort="Eckmanns, T" uniqKey="Eckmanns T" first="T" last="Eckmanns">T. Eckmanns</name><name sortKey="Hellenbrand, W" sort="Hellenbrand, W" uniqKey="Hellenbrand W" first="W" last="Hellenbrand">W. Hellenbrand</name><name sortKey="Krause, G" sort="Krause, G" uniqKey="Krause G" first="G" last="Krause">G. Krause</name><name sortKey="Poggensee, G" sort="Poggensee, G" uniqKey="Poggensee G" first="G" last="Poggensee">G. Poggensee</name><name sortKey="Stocker, P" sort="Stocker, P" uniqKey="Stocker P" first="P" last="Stocker">P. Stocker</name><name sortKey="Walter, D" sort="Walter, D" uniqKey="Walter D" first="D" last="Walter">D. Walter</name></noCountry><country name="Allemagne"><region name="Berlin"><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000343 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000343 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20460094
|texte= Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20460094" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |